Singapore's Gero Raises $17 Million to Advance Aging Research
Gero, a Singapore-based company dedicated to transforming human aging through the integration of physics and artificial intelligence, announced on June 17, 2026, that it has secured $17 million in new funding. This latest round saw participation from Melnichek Investments, although the specific details of the funding round were not disclosed.
Company Vision and Leadership
Founded by Peter Fedichev and Max Kholin, Gero is at the forefront of utilizing advanced AI technologies to explore the complexities of human aging. The company aims to leverage scientific insights to develop interventions that could potentially prolong healthy life spans.
Peter Fedichev, the Co-founder and CEO, has been instrumental in steering the company's innovative approach to aging. "Our mission is to decode the biological processes behind aging and apply that knowledge to improve health outcomes," Fedichev has emphasized in past communications.
Strategic Use of Funds
While specific plans for the newly acquired funds were not detailed in the announcement, it is expected that Gero will continue to invest in its research and development capabilities. This may include expanding its team of scientists and AI experts, enhancing its technological infrastructure, and potentially exploring new partnerships that align with its mission of addressing the challenges of aging.
Investor Confidence
The participation of Melnichek Investments in this funding round underscores the growing interest and confidence in Gero's innovative approach. Although no lead investor was specified, the involvement of such a notable investor highlights the potential impact of Gero's work in the field of biogerontology.
Outlook
As Gero continues to push the boundaries of what is scientifically possible in the realm of aging, the infusion of $17 million will likely provide a significant boost to its ongoing projects. With a strong foundation in AI and a clear focus on aging, Gero is well-positioned to make meaningful contributions to the healthcare and biotechnology sectors.
The company's advancements could pave the way for new therapies and interventions that could transform how society approaches aging and longevity, making it a key player to watch in the coming years.